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a b s t r a c t
This study investigated the coagulation status of dogs with immune-mediated haemolytic anaemia
(IMHA) over time. Thirty animals with primary IMHA were blood sampled on three occasions over a
5 day period and assays performed included prothrombin time, activated partial thromboplastin time,
D-dimer and fibrinogen concentration, antithrombin activity and recalcified unactivated thromboelastog-
raphy (TEG).
Based on TEG, dogs with IMHA were significantly hypercoagulable vs. controls (P < 0.001) and over the
5 day period, 3/4 of the TEG parameters reflected increased clotting kinetics (P 6 0.02). The 30 day sur-
vival of these patients was 80% and, at hospital admission, the TEG maximum amplitude (MA) was sig-
nificantly higher in survivors than non-survivors (P = 0.015). Each unit increase in MA was associated
with an increased odds of 30 day survival of 1.13 (95%; CI 1.02–1.25). Based on TEG, most dogs with IMHA
were hypercoagulable on admission and their clotting kinetics increased with time. Relative hypocoagu-
lability identified by TEG at initial assessment was found to be a negative prognostic indicator.
! 2011 Elsevier Ltd. All rights reserved.
Introduction
Various coagulation abnormalities have been documented in
dogs with immune-mediated haemolytic anaemia (IMHA) includ-
ing disseminated intravascular coagulation (DIC) and a hypercoag-
ulable state (Mischke, 1998; Scott-Moncrieff et al., 2001; Carr
et al., 2002). IMHA in dogs is associated particularlywith pulmonary
thromboembolism (Bunch et al., 1989; Klein et al., 1989; Johnson
et al., 1999) but thrombosis has also been identified at other sites
including the cranial vena cava (Palmer et al., 1998), portal vein
(Van Winkle and Bruce, 1993), heart, spleen and kidney (McManus
and Craig, 2001; Carr et al., 2002). There is an association between
IMHA and a prothrombotic state and thromboembolism is linked
with poor clinical outcome (Klag et al., 1993; Scott-Moncrieff
et al., 2001; Carr et al., 2002). Mechanisms proposed for the gener-
ation of thromboembolism in IMHA include cytokine-induced
monocyte and endothelial tissue factor expression (Hoffman,
2006), erythrocyte phosphatidylserine exposure (Ataga et al.,
2007), procoagulant microparticle release (Horne et al., 2006) and
the presence of anti-phospholipid antibodies (Pullarkat et al., 2002).
Until recently clinical recognition of hypercoagulability was
difficult. Thromboelastography (TEG) is a patient-side, viscoelastic
assessment of coagulation, which provides a graphical
representation of clot formation over time (Kol and Borjesson,
2010; Wiinberg and Kristensen, 2010). TEG has been used to iden-
tify hypercoagulability in dogs with parvoviral enteritis (Otto et al.,
2000), neoplasia (Kristensen et al., 2008), DIC (Wiinberg et al.,
2008) and protein losing nephropathy (Hilling et al., 2009). The
velocity curve (Vcurve) is a computed parametric derivative of a
conventional TEG profile which enables quantification of the kinet-
ics of clot propagation. The results of this analysis are similar to the
parameters produced by DyCoDerivaAu software derived from
Rotem tracings (Sorensen et al., 2003) and the TEG Vcurve has been
described for plasma (Nielsen et al., 2004) and whole blood (Ellis
et al., 2004).
A recent retrospective study reported the use of TEG to identify
hypercoagulability in dogs with IMHA (Sinnott and Otto, 2009).
Consistent with previous reports linking thrombosis with poor out-
come in cases of IMHA, Sinnott and Otto (2009) hypothesised that
dogs with IMHA would be hypercoagulable and that the resultant
TEG profiles would be associated with a poor outcome. The study
unexpectedly identified that no animals with a normal coagulation
index survived, suggesting that dogs which were not hypercoagu-
lable had a greater risk of death. This result appears counter-
intuitive. One interpretation is that animals with IMHA and normal
coagulation indices are relatively hypocoagulable, potentially con-
sistent with the presence of a consumptive coagulopathy. Thus a
normal TEG profile in a dog with IMHAmay not preclude the ongo-
ing existence of such a coagulopathy.
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Although hypercoagulability has been identified in dogs with
IMHA using TEG, the retrospective study of Sinnott and Otto
(2009) was limited by a lack of standardisation of timing of TEG
or concurrent analyses. Serial TEG was not performed and thus it
remains unknown how treatment may alter these profiles. Cortico-
steroids, the mainstay of therapy for IMHA, are associated with an
increased risk of thromboembolic complications (Van Winkle and
Bruce, 1993; Palmer et al., 1998). Alterations in coagulation associ-
ated with corticosteroid administration have also been demon-
strated with TEG, wherein prednisolone (at 1 mg/kg or 4 mg/kg,
once daily) significantly altered the TEG clot formation time (K),
clot formation angle (a), and maximum amplitude (MA) values
consistent with a hypercoagulable profile (Rose et al., 2008).
Whereas corticosteroids in normal dogs induce hypercoagulable
TEG profiles, in animals with IMHA the immunosuppression should
resolve the hypercoagulability. As a result, the effect of steroid
therapy on the TEG profiles of dogs with IMHA is difficult to
predict.
The objectives of this study were to investigate hypercoagula-
bility in naturally occurring cases of IMHA in dogs using TEG and
to assess changes in coagulation status over time in treated ani-
mals. Based on the results of Sinnott and Otto (2009), we hypoth-
esised that dogs with IMHA would be hypercoagulable on initial
assessment and those that did not demonstrate hypercoagulability
would have a poorer survival rate. We also hypothesised that ther-




The study was approved by the Royal Veterinary College Ethics and Welfare
Committee.
A cohort of 30 dogs with IMHA was selected based on sample size calculations
(Uitenbroek, 1997; Otto et al., 2000), which suggested that this number would be
required to detect two-way differences between groups in MA and reaction time
(R) with 80% power. Dogs admitted to the Queen Mother Hospital for Animals
(QMHA), The Royal Veterinary College (RVC), London, between January 2008 and
October 2009 and diagnosed with primary IMHA were considered eligible. The
diagnostic criteria were: anaemia with a PCV <37% and a positive in-saline aggluti-
nation test, Coombs’ test or moderate-to-marked spherocytosis on a blood smear;
no evidence of underlying disease. Patients were not eligible if their platelet count
was <100,000/lL in order to exclude dogs with an Evans-like syndrome. To facili-
tate case recruitment dogs were selected provided they had not received corticoste-
roids for >3 days previously, in line with a previous study (Mitchell et al., 2009).
Dogs receiving aspirin, clopidogrel, unfractionated or low-molecular weight hepa-
rin or warfarin were also excluded.
Signalment, clinical history, results of clinical examination and clinicopatholog-
ical data were recorded on admission to the QMHA. To enable objective assessment
of disease severity in the study population, the canine haemolytic anaemia objec-
tive score (CHAOS) was calculated (Whelan et al., 2006). Assessment of the inflam-
matory status of the dogs was based on published criteria (Okano et al., 2002). To
exclude cases of secondary IMHA, all dogs underwent diagnostic evaluations at
the discretion of the attending clinician including: abdominal ultrasound (n = 30);
thoracic radiography (n = 29); urine culture (n = 27); urinalysis (n = 26); PCR
screening for tick-borne disease where there was a history of travel outside of
the UK (n = 5).
Patient sampling
Blood samples were collected by jugular venepuncture using a 21 G needle and
a 10 mL syringe and were immediately aliquoted into 1.1 mL or 1.3 mL non-vac-
uum, polypropylene tubes (Pediatric tube, International Scientific Supplies). Sam-
ples for complete blood counts (CBC) were collected into potassium EDTA tubes.
Samples for serum biochemistry and C-reactive protein (CRP) were collected into
gel separator tubes. For TEG, prothrombin time (PT), activated partial thrombo-
plastin time (aPTT), antithrombin activity (AT), fibrinogen (Fg) and D-dimer deter-
minations, blood was collected into tubes containing 3.2% liquid sodium citrate. On
days 0 and 3, CBCs, serum biochemistry, CRP, PT, aPTT, Fg, AT, D-dimers and TEG
were carried out on 10 mL of blood. On day 5, CRP, Fg, AT and TEG were performed
using 5 mL of blood. Owing to financial constraints, a CBC was not performed on the
day 5 samples. Blood PCV was measured at each time-point.
Sample analysis
CBCs and serum biochemistry were performed using automated analysers (Cell-
Dyn 2500, Abbott Laboratories and ILAB 600, Instrumentation Laboratory). Pro-
thrombin and aPTTs were measured on citrated whole blood using a ‘point-of-care’
analyser (CoagDx, IDEXX). D-dimers were assayed by a commercial laboratory
using a latex agglutination method (Helena Biosciences). C-reactive protein (CRP)
was measured using an automated human turbidimetric assay validated for canine
use (Kjelgaard-Hansen et al., 2003; Kjelgaard-Hansen, 2010) calibrated with puri-
fied canine CRP (LifeDiagnostics). Samples for Fg and AT were assayed by the Clauss
method and chromogenic assay, respectively.
Thromboelastography
All samples were run on a single machine (TEG 5000 Haemostasis Analyser,
Haemoscope Corporation) according to the manufacturer’s instructions. To avoid
time-dependent alterations in TEG parameters, samples were held at room temper-
ature for 30 min prior to analysis (Bowbrick et al., 2000; Wiinberg et al., 2005). The
assays were run for 90 min. All TEG tracings were produced using a recalcified,
unactivated assay. Thromboelastography was performed using a heparinase cup
in dogs with in-dwelling IV catheters or in those receiving heparin (n = 73). Plain
TEG cups were only used in dogs not receiving any form of heparin (n = 7).
Four variables were recorded from the TEG tracings: R; K; MA; and a. Three
variables were recorded from the corresponding Vcurve tracings: maximum rate of
thrombus generation (MRTG); time to maximum rate of thrombus generation
(TMRTG); and total thrombus generated (TG). Recalcified, unactivated TEG tracings
were produced from a control population of 30 healthy dogs (HC), selected from the
hospital blood donation programme. These dogs were considered healthy on the
basis of: clinical examination; CBC and serum biochemistry profile; and absence
of travel outside the UK.
Statistical analysis
Prior to test selection, data were assessed for normality. Although some vari-
ables were parametric, most were not and thus non-parametric tests were used
throughout. Wilcoxon signed-rank tests were used to compare TEG results from
dogs with IMHA with controls and to compare pre- and post-treatment TEG values.
Calculation of the Spearman’s rank correlation coefficient was used to assess
relationships of continuous clinicopathological variables with TEG values. The
Chi-square or Fisher’s exact tests were used to compare categorical variables. Binary
logistic regression was used to identify predictors of outcome. All analyses were
conducted using commercial statistical software (SPSS 16 for Windows, SPSS Inc.)
with a set at 0.05. Where multiple comparisons were undertaken the P value was




Although 34 dogs were initially selected, four were excluded
because of neoplasia (n = 2) and thrombocytopaenia (n = 2). The
30 remaining dogs had a mean age of 6.7 ± 3.1 years and were of
13 different breeds including: English Springer spaniel (n = 8);
Cocker spaniel (n = 7); Labrador retriever (n = 2); and Staffordshire
bull terrier (n = 2). There was one Bedlington terrier, Border collie,
Dachshund, Golden retriever, Jack Russell terrier, Miniature
schnauzer, Shih Tzu, Weimeraner and West Highland white terrier
and two crossbred animals.
A high proportion of the study population was female (23/30,
76.7%), of which 19 were neutered. Five of the seven males were
neutered. The median duration of clinical signs prior to presenta-
tion was 3 days (1–7). Ten dogs had received no treatment prior
to presentation. Thirteen animals had been given corticosteroids
prior to presentation with some dogs receiving more than one
drug: prednisolone (n = 9); dexamethasone (n = 5); and methyl-
prednisolone (n = 1). The median duration of prior corticosteroid
therapy was 1 day (1–3). Other treatments included clavulanate-
potentiated amoxicillin (n = 6), vitamin K, sucralfate, ranitidine,
azathioprine (each n = 3), enrofloxacin (n = 2), metronidazole
(n = 2), and opioids (n = 2). Three dogs received fresh whole blood
prior to presentation and one animal had been given a haemoglo-
bin-based oxygen carrying solution (HBOC) (Oxyglobin, Biopure).
348 R. Goggs et al. / The Veterinary Journal 191 (2012) 347–353
On presentation the mean heart rate was 133 ± 23 bpm, the
mean respiratory rate was 41 ± 17 bpm and the mean rectal tem-
perature 38.6 ± 0.6 "C. All dogs had pale mucous membranes and
14 displayed clinical evidence of jaundice. Seven dogs had audible
systolic murmurs (all 63/6) and all 30 animals were in-saline
agglutination positive. The initial clinicopathological findings are
summarised in Table 1. Fifteen dogs were positive for systemic
inflammatory response syndrome (SIRS) (Okano et al., 2002) and
the median CHAOS score was 3 (2–6; maximum score 7). All the
treatments administered at the QMHA are listed in Table 2.
Clinical outcomes
Twenty-five dogs were discharged alive and three died during
hospitalisation: one due to uncontrollable haemolysis (on day 4);
one due to secondary acute kidney failure (on day 5); and one due
to suspected pulmonary thromboembolism (on day 2). A necropsy
on the latter dog did not identify pulmonary emboli but did identify
thrombi in the hepatic sinusoids, suggesting that this dogmay have
died of thromboembolic complications. Two dogs were euthanased
during hospitalisation: one following acute clinical deterioration
(on day 3) and another following failure to respond to therapy (on
day 10). Neither of these cases was available for necropsy.
Of the 25 dogs discharged from the hospital, 24 were alive
30 days post-admission and 17 were still alive 6 months post-
admission (equivalent to a 58.6% 6 month survival rate). One dog
was ‘lost’ to follow-up. Althoughmedian CHAOS values for non-sur-
vivorswerehigher than for survivors indicatingmore severedisease,
the differencewas not significant at time-of-discharge fromhospital
or at 30 days post-admission. Neither the SIRS status (Okano et al.,
2002), nor any of the other clinicopathological variables testedwere
predictive of clinical outcome at either of these time-points.
Thromboelastography
At admission, none of the TEG variables were significantly dif-
ferent between dogs treated and not treated with corticosteroids.
At hospital admission, compared to controls, dogs with IMHA
had significantly shorter K times, greater a angles and greater
MA values (all P < 0.001) consistent with a hypercoagulable state.
The TEG variables changed significantly following initiation of
therapy (Table 3). From admission to day 3 there were significant
decreases in R (P = 0.023) and K (P = 0.006) and a significant in-
crease in a (P = 0.012). At day 5, all TEG variables were significantly
different from those at admission: R and K were significantly de-
creased (P 6 0.001); MA was significantly decreased (P = 0.021);
and a was significantly increased (P = 0.003) (Fig. 1).
At day 5 all of the TEG values remained significantly different
from those of the controls (P 6 0.002) with tracings having a more
hypercoagulable profile over time, except for the MA values which
decreased. Based on Vcurve analysis, the MRTG increased signifi-
cantly between admission and day 5 (P = 0.012) and the TMRTG
decreased significantly over the same time period (P = 0.001).
There was a significant decrease in TG between admission and
day 5 (P = 0.031) (Table 3).
A number of variables correlated with the TEG derived MA val-
ues at admission. Maximum amplitude positively correlated with
Fg concentration (r = 0.790, P < 0.001; n = 28) and with AT activity
(r = 0.532, P = 0.004; n = 28). Maximum amplitude negatively
correlated with PCV (r = !0.451, P = 0.012; n = 30). Maximum
amplitude did not significantly correlate with platelet count or
with D-dimer concentration. Of the TEG variables, only MA was
predictive of outcome. The MA at time of admission was signifi-
cantly higher in survivors vs. non-survivors at discharge
(P = 0.016) and at 30 days post-admission (P = 0.015) (Fig. 2). Logis-
tic regression analysis suggested each unit increase in MA was
associated with increased odds of 30 day survival of 1.13 (95%; CI
1.02–1.25).
Other clinicopathological findings
There were no significant correlations between R, K or a and
clotting times although aPTT values negatively correlated with
MA at time of admission (r = !0.529, P = 0.0026; n = 28). In all 28
Table 1
Summary clinicopathological data from 30 dogs with immune-mediated haemolytic anaemia at the time of admission to The Queen Mother Hospital for Animals. Reference
intervals are those determined at and used in the hospital with the exception of the thromboelastography variables which represent the values from the 30 healthy controls
(italicised).
Variable Median Range n n below interval n above interval Reference interval
Albumin (g/L) 29.7 18–39.5 29 12 1 28–39
ALT (l/L) 53 10–1671 29 1 12 13–88
ALP (l/L) 228 88–2185 29 0 13 19–285
Bilirubin (lmol/L) 41 2–1259 29 – 28 0–2
Neutrophils ("109/L) 21.5 6.2–57.8 30 0 24 3–11.5
Band neutrophils ("109/L) 0.9 0–5.9 30 – 19 0–0.3
Monocytes ("109/L) 2.7 0.4–12.2 30 0 24 0.15–1.5
Platelet count ("109/L) 192 112–400 30 4 0 150–450
Absolute reticulocyte count (cells/lL) 155,400 1820–576,978 19 – – –
PCV (%) 14.5 7–35 30 30 0 37–55
R (min) 14.0 6.5–24.8 30 5 2 9.1–20.3
K (min) 4.2 1.6–11.1 30 16 0 4.3–13.1
a angle (") 45.3 20.3–71.8 30 0 19 17.0–42.4
MA (mm) 69.7 44.8–85.4 30 0 28 33.5–49.0
MRTG (mm/min) 6.7 1.9–20.3 30 0 21 1.5–4.7
TMRTG (min) 18.5 8.8–36.0 30 5 3 11.6–27.6
TG (mm/min) 840.7 548.6–1025.4 30 0 28 396–595
D-dimers (ng/mL) 500–1000 <250–>2000 30 – 23 <250
C-reactive protein (mg/L) 137 30.4–438.6 27 – 27 0–8.9
Fibrinogen (lmol/L) 35.9 15–71.4 28 0 28 4.3–14.1
AT (%) 94 63–125 28 2 0 65–145
PT (s) 14 9–19 29 3 1 12–17
aPTT (s) 106.5 92–150 28 0 18 71–102
a, clot formation angle; ALT, alanine aminotransferase; ALP, alkaline phosphatase; aPTT, activated partial thromboplastin time; AT, antithrombin activity; K, clot formation
time; MA, maximum amplitude; MRTG, maximum rate of thrombus generation; PCV, packed cell volume; PT, prothrombin time; R, reaction time; TG, total thrombus
generated; TMRTG, time to maximal rate of thrombus generation.
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animals in which Fg concentrations were measured, the value was
above normal at admission. Median Fg concentrations decreased
between time of admission and day 5 but this was not significant
(P = 0.066) and at day 5, 91% of dogs still had abnormally high Fg
concentrations. At admission, CRP concentrations were abnormally
high in all 27 dogs in which this parameter was measured. There
was a positive correlation between Fg and CRP concentrations at
time of admission (r = 0.576, P < 0.001; n = 27). By day 5, median
CRP concentrations reduced significantly (P < 0.001), although 21/
23 values remained abnormal. At time of admission, three dogs
had AT activities below the reference interval. AT activity reduced
significantly between admission and day 5 (P = 0.012) such that by
day 5, 36% of dogs had subnormal AT activities.
Discussion
Of the clinicopathological and TEG parameters assessed, only
MA at initial presentation was significantly associated with out-
come in this prospective study of dogs with IMHA. The results
are consistent with those of previous studies (Sinnott and Otto,
2009; Flint et al., 2010). Based on the TEG parameters, dogs with
IMHA exhibited evidence of hypercoagulability with significantly
shorter K times, greater a and higher MAs than controls. This indi-
cates that affected dogs have both increased clotting kinetic activ-
ity and achieve higher total clot strengths. Consistent with our
findings, a small study of 11 dogs identified significantly shorter
K times, larger a angles and higher MA values in dogs with IMHA
at time of admission to hospital (Fenty et al., 2011). The cause of
this hypercoagulability is likely multifactorial including hyperfibri-
nogenaemia, increased contact pathway activation, platelet hyper-
reactivity (Weiss and Brazzell, 2006), haemolysis (Bauer et al.,
2010) and the effects of immunosuppressive drugs.
Within the first 5 days of therapy, R, K and a changed signifi-
cantly in a manner consistent with increased clotting kinetics.
The changes in the Vcurve parameters, MRTG and TMRTG are also
consistent with an increase in the rate of clot propagation over this
time period. Indeed, since the conventional TEG values are non-
parametric, clot propagation expressed as MRTG may provide a
more accurate assessment of clot kinetics than either MA or a (Ellis
et al., 2004). Decreased K and increased amay reflect contempora-
Table 2
Summary of treatments administered to the 30 dogs with immune-mediated haemolytic anaemia following admission to The Queen Mother Hospital for Animals. All dogs were
given corticosteroids, typically both dexamethasone and prednisolone. Where more than one corticosteroid was administered, this was given sequentially and not
contemporaneously. Data is presented as median (range) unless otherwise specified. Types of therapeutic intervention are grouped together in the table.
Treatment n Median dose (range) Frequency
Prednisolone (generic) 26 2 mg/kg (1.67–2.2) Twice daily
Dexamethasone (Dexadreson, Intervet) 24 0.3 mg/kg (0.25–0.5) Once daily
Azathioprine (Imuran, GlaxoSmithKline) 16 2 mg/kg (1.44–2.2) Once daily
Mycophenolate mofetil (Cellcept, Roche) 6 16.3 mg/kg (10–20) Once daily
Cyclosporine (Atopica, Novartis) 3 5 mg/kg (5–10) Twice daily
Human immunoglobulin (Kiovig, Baxter) 2 0.49 g/kg and 0.67 g/kg Single dose
Packed red blood cells 26 22.6 mL/kg (6.6–46.7) –
Fresh whole blood 2 18.7 mL/kg and 27 mL/kg Single doses
Haemoglobin-based oxygen carrying (HBOC) solution (Oxyglobin, Biopure) 2 16.9 mL/kg and 375 mL/kg Single doses
Fresh frozen plasma 1 25 mL/kg Single dose
Omeprazole (Losec, AstraZeneca) 12 All 1 mg/kg Once daily
Sucralfate (Antepsin, Chugai Pharma) 2 Both 0.5 g Three times daily
Aspirin (generic) 29 All 0.5 mg/kg Once daily
Clopidogrel (Plavix, SanofiAventis) 1 1.1 mg/kg Once daily
Dalteparin (Fragmin, Pfizer) 3 All 150 l/kg Three times daily
Unfractionated heparin (generic) 1 200 l/kg Three times daily
Table 3
Summary coagulation test data from the 30 dogs with immune-mediated haemolytic anaemia at time of admission (day 0), on day 3 and on day 5. P values correspond to
comparisons between admission (day 0) and day 5 apart from those values indicated by # where the P value corresponds to the comparison between admission (day 0) and day 3.
Bold font signifies significance at P < 0.05 or, where applicable, after adjustment for multiple comparisons.
Variable (unit) On admission (Day 0) Day 3 Day 5 P
Median (range) n Median (range) n Median (range) n
R (min) 14.0 (6.5–24.8) 30 10.9 (5.7–22.9) 27 9.8 (4–22.9) 23 <0.001
K (min) 4.2 (1.6–11.1) 30 2.8 (1.3–13.1) 27 2.4 (0.9–10.4) 23 0.001
a (") 45.3 (20.3–71.8) 30 54.0 (17.7–71.2) 27 60.2 (21.8–76.3) 23 0.003
MA (mm) 69.7 (44.8–85.4) 30 67.1 (47.8–82.5) 27 66.7 (49.5–81.8) 23 0.021
MRTG (mm/min) 6.7 (1.9–20.3) 30 8.9 (2.2–19.0) 27 11.5 (2.7–23.2) 23 0.012
TMRTG (min) 18.5 (8.8–36.0) 30 13.8 (8.7–37.9) 27 12.3 (4.9–34.8) 23 0.001
TG (mm/min) 840.7 (548.6–1025.4) 30 803.4 (580.2–988.5) 27 806.9 (587.2–979.9) 23 0.031
Platelet count ("109/L) 200 (110–400) 30 165 (50–400) 27 – – 0.882#
Fibrinogen (lmol/L) 35.9 (15–71.4) 28 26.7 (10.7–76.9) 24 25 (6.9–43.7) 11 0.066
Antithrombin (% normal) 94 (63–125) 28 72.5 (46–100) 24 69 (48–88) 11 0.012
C-reactive protein (mg/L) 137 (30.4–438.6) 27 57.7 (7–336.6) 26 38 (2.9–156.7) 23 <0.001
D-dimers (ng/mL) 500–1000 (<250–>2000) 30 1000–2000 (<250–>2000) 27 – – 0.089#
PT (s) 14 (9–19) 29 12.5 (11–18) 24 – – 0.633#
aPTT (s) 106.5 (92–150) 28 100 (80–122) 23 – – 0.007#
PCV (%) 14.5 (7–35) 30 22 (4–34) 27 24 (15–39) 23 0.003
a, clot formation angle; aPTT, activated partial thromboplastin time; AT, antithrombin activity; K, clot formation time; MA, maximum amplitude; MRTG, maximum rate of
thrombus generation; PCV, packed cell volume; PT, prothrombin time; R, reaction time; TG, total thrombus generated; TMRTG, time to maximal rate of thrombus generation.
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neous decreases in AT due to consumption secondary to increased
thrombin production. The concomitant decreases in R and aPTT
suggest increased contact pathway activation may be the source
of thrombin activation.
There are several potential explanations for this increase in con-
tact pathway activation. Platelet activation, known to be increased
in IMHA (Weiss and Brazzell, 2006), may occur through leucocyte
interactions (Li, 2008), or nitric-oxide depletion (Rother et al.,
2005), contributing to contact pathway activation through in-
creased tenase complex assembly. Ongoing haemolysis may also
contribute through continued generation of phosphatidylserine-
bearing erythrocyte-derived microparticles (Horne et al., 2006).
Corticosteroid therapy may also be partly responsible (Jacoby
et al., 2001) since hypercortisolism in both humans and dogs is
associated with significantly increased concentrations of factors
VIII, IX and XII (Chandler, 1995; Van Zaane et al., 2009). Increased
thrombin generation, by promoting the development of DIC, might
be one of the mechanisms responsible for the development of or-
gan dysfunction or of thrombosis in dogs with IMHA.
The decrease in MA and in the Vcurve parameter TG between
admission and day 5 were the only TEG-derived changes consistent
with decreased hypercoagulability. However at all time-points the
MA and TG values indicated significant hypercoagulability com-
pared to controls and the decreases in MA and TG, while statisti-
Fig. 1. ‘Box and whisker’ plots of thromboelastography variables from dogs with immune-mediated haemolytic anaemia at admission, and at post-admission days 3 and 5,
compared to controls. The middle lines represent the median, the boxes represent inter-quartile ranges and whiskers the 95th percentiles. Values outside the 95th and 99th
percentiles are represented as open circles and by #, respectively. (A–D) illustrate reaction time (R), clot formation time (K), clot formation angle (a) and maximum amplitude
(MA) values, respectively.
Fig. 2. ‘Box and whisker’ plots comparing the thromboelastography maximum
amplitude (MA) values at hospital admission of surviving dogs, with those of
animals that did not survive to 30 days post-admission. The MA values of non-
survivors were significantly lower (P = 0.015).
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cally significant, were small in magnitude compared with other
TEG variables. Maximum amplitude is positively correlated with
platelet number, platelet function, Fg and thrombin generation
(Chandler, 1995) and is negatively correlated with haematocrit
(Zuckerman et al., 1981).
Identification of hypercoagulability in dogs with IMHA using
TEG is hampered by the anaemia because of the inverse relation-
ship between haematocrit and MA (Iselin et al., 2001; Spiezia
et al., 2008). However, if the hypercoagulability documented by
MA was solely due to alterations in haematocrit, it might be ex-
pected that the PCV would be associated with outcome: this was
not the case. In the dogs in the current study, the MAwas more clo-
sely correlated with Fg concentration (r = 0.790) and was only
moderately correlated with PCV (r = !0.451). Thus it is likely that
some, but not all, of the increase in MA was due to anaemia. The
use of euvolaemic, haemo-depleted controls produced by phlebot-
omy with autologous platelet-rich plasma transfusions might facil-
itate the evaluation of the specific contribution of haematocrit to
the MA abnormalities observed.
The hyperfibrinogenaemia observed in the dogs in our study
was likely associated with the inflammatory response since Fg
and CRP concentrations were positively correlated. The strong cor-
relation between Fg and MA in this study suggests the Fg concen-
tration and hence the inflammatory response contributes
significantly to the pathogenesis of the hypercoagulable syndrome
in IMHA. Since platelet count has been reported to directly corre-
late with MA, the lack of correlation between platelet count and
MA in our study is interesting. This may have been due to our
exclusion criteria, which, by excluding patients with platelet
counts <100,000/lL, may have reduced the platelet count variabil-
ity in the study population.
By day 5, the PCV significantly increased while Fg concentra-
tions decreased although not significantly. The platelet count also
decreased between admission and day 3 although not significantly.
Nevertheless, these variables may all have contributed to the de-
crease in MA over time. If the decrease in MA values were associ-
ated with a consumptive coagulopathy we would have expected to
find that the animals with low MA values had higher concentra-
tions of D-dimers and lower ATs. We might also have expected
the platelet count, Fg concentration and AT to fall over time due
to consumption. Indeed, MA directly correlated with AT and the
platelet count, Fg concentration and AT also all decreased over
time. The median D-dimer value increased between admission
and day 3 although MA and D-dimer concentrations were not sig-
nificantly correlated. As such, the correlations between the TEG
variables and the other measures of coagulation are consistent
with the hypothesis proposed by Sinnott and Otto (2009) that a
consumptive coagulopathy is responsible for the poorer outcome
in patients with lower MA values on presentation.
This study is not without its limitations. Due to financial con-
straints not all tests were run at every time-point: D-dimer concen-
trations and platelet counts were not determined at day 5. Although
the recalcified, unactivatedTEGassaymayhavehigher inherent var-
iability than the tissue factor or kaolin activated assays (Bauer et al.,
2009), these assays were either not available to us or the work
reporting their use had not been published at the commencement
of our study. Similarly, we did not run complete factor analyses or
assay fibrinolytic proteins, which might have provided additional
information regarding the cause of the hypercoagulability.
Approximately half of the affected dogs in this study had re-
ceived corticosteroids prior to hospital admission. No statistically
significant differences were identified in the TEG parameters at
presentation between dogs that had received such prior treatment
and those that had not. However, given that corticosteroid admin-
istration to dogs is known to affect these parameters (Rose et al.,
2008), we cannot exclude the possibility that this may have biased
our results. In our study population, there was marked heterogene-
ity in the treatments administered. This lack of uniformity poten-
tially introduces confounding factors which make it more
difficult to relate cause and effect. Despite this heterogeneity how-
ever, the observation that MA was predictive of outcome appears
significant and is consistent with previous findings (Sinnott and
Otto, 2009; Flint et al., 2010).
Although we propose that relative hypocoagulability in IMHA is
associated with a poor prognosis due to a consumptive coagulopa-
thy, the lack of association between a ‘hypercoagulable’ TEG trac-
ing and outcome remains puzzling. Does such a tracing truly
represent an in vivo hypercoagulable state? A longitudinal study
evaluating the association between TEG parameters and the risk
of thrombosis will be required to address this question. Such a
study will necessitate the involvement of multiple veterinary hos-
pitals in order to provide sufficient statistical power given the inev-
itable heterogeneity in the disease population.
Conclusions
The results of this study indicate that TEG MA values at hospital
admission are predictive of clinical outcome in dogs with IMHA. All
the animals had TEG profiles consistent with hypercoagulability
during hospitalisation, a state which was likely multifactorial in
origin. Our data support the previously suggested hypothesis that
consumptive coagulopathy is responsible for the poorer outcome
in dogs with lower MA values on presentation. Thromboelasto-
graphic tracings thus appear to be predictive of outcome and as
such should be considered integral to the assessment of dogs with
IMHA.
Conflict of interest statement
None of the authors of this paper has a financial or personal
relationship with other people or organisations that could inappro-
priately influence or bias the content of this paper.
Acknowledgement
This study was funded in part by The Petplan Charitable Trust
(Project number 07-34) and The Waltham Foundation.
References
Ataga, K.I., Cappellini, M.D., Rachmilewitz, E.A., 2007. Beta-thalassaemia and sickle
cell anaemia as paradigms of hypercoagulability. British Journal of
Haematology 139, 3–13.
Bauer, N., Eralp, O., Moritz, A., 2009. Establishment of reference intervals for kaolin-
activated thromboelastography in dogs including an assessment of the effects
of sex and anticoagulant use. Journal of Veterinary Diagnostic Investigation 21,
641–648.
Bauer, N., Eralp, O., Moritz, A., 2010. Effect of hemolysis on canine kaolin-activated
thromboelastography values and ADVIA 2120 platelet activation indices.
Veterinary Clinical Pathology 39, 180–189.
Benjamini, Y., Yekutieli, D., 2001. The control of the false discovery rate in multiple
testing under dependency. Annals of Statistics 29, 1165–1188.
Bowbrick, V.A., Mikhailidis, D.P., Stansby, G., 2000. The use of citrated whole blood
in thromboelastography. Anesthesia and Analgesia 90, 1086–1088.
Bunch, S.E., Metcalf, M.R., Crane, S.W., Cullen, J.M., 1989. Idiopathic pleural effusion
and pulmonary thromboembolism in a dog with autoimmune hemolytic
anemia. Journal of the American Veterinary Medical Association 195, 1748–
1753.
Carr, A.P., Panciera, D.L., Kidd, L., 2002. Prognostic factors for mortality and
thromboembolism in canine immune-mediated hemolytic anemia: A
retrospective study of 72 dogs. Journal of Veterinary Internal Medicine 16,
504–519.
Chandler, W.L., 1995. The thromboelastography and the thromboelastograph
technique. Seminars in Thrombosis and Hemostasis 21, 1–6.
Ellis, T.C., Nielsen, V.G., Marques, M.B., Kirklin, J.C., 2004. Thromboelastographic
measures of clot propagation: A comparison of alpha with the maximum rate of
thrombus generation. Blood Coagulation and Fibrinolysis 18, 45–48.
352 R. Goggs et al. / The Veterinary Journal 191 (2012) 347–353
Fenty, R.K., Delaforcade, A.M., Shaw, S.E., O’Toole, T.E., 2011. Identification of
hypercoagulability in dogs with primary immune-mediated hemolytic anemia
by means of thromboelastography. Journal of the American Veterinary Medical
Association 238, 463–467.
Flint, A., Abrams-Ogg, S., Kruth, S., Bersenas, A.,Wood, R., 2010. Thromboelastography
in dogs with immune-mediated hemolytic anemia treat with prednisone,
azathioprine and low-dose aspirin. Journal of Veterinary Internal Medicine 24,
681.
Hilling, K.M., Labato, M.A., de Laforcade, A.M., Shaw, S., 2009. Documentation of
hypercoagulability in protein-losing nephropathy via thromboelastography in
10 dogs. Journal of Veterinary Internal Medicine 23, 690.
Hoffman, P.C., 2006. Immune hemolytic anemia – selected topics, hematology.
American Society of Hematology Education Program 1, 13–18.
Horne III, M.K., Cullinane, A.M., Merryman, P.K., Hoddeson, E.K., 2006. The effect of
red blood cells on thrombin generation. British Journal of Haematology 133,
403–408.
Iselin, B.M., Willimann, P.F., Seifert, B., Casutt, M., Bombeli, T., Zalunardo, M.P.,
Pasch, T., Spahn, D.R., 2001. Isolated reduction of haematocrit does not
compromise in vitro blood coagulation. British Journal of Anaesthesia 87,
246–249.
Jacoby, R.C., Owings, J.T., Ortega, T., Gosselin, R., Feldman, E.C., 2001. Biochemical
basis for the hypercoagulable state seen in Cushing syndrome. Archives of
Surgery 136, 1003–1006.
Johnson, L.R., Lappin, M.R., Baker, D.C., 1999. Pulmonary thromboembolism in 29
dogs: 1985–1995. Journal of Veterinary Internal Medicine 13, 338–345.
Kjelgaard-Hansen, M., 2010. Comments on measurement of C-reactive protein in
dogs. Veterinary Clinical Pathology 39, 402–404.
Kjelgaard-Hansen, M., Jensen, A.L., Kristensen, A.T., 2003. Evaluation of a
commercially available human C-reactive protein (CRP) turbidometric
immunoassay for determination of canine serum CRP concentration.
Veterinary Clinical Pathology 32, 81–87.
Klag, A.R., Giger, U., Shofer, F.S., 1993. Idiopathic immune-mediated hemolytic
anemia in dogs: 42 cases (1986–1990). Journal of the American Veterinary
Medical Association 202, 783–788.
Klein, M.K., Dow, S.W., Rosychuk, R.A., 1989. Pulmonary thromboembolism
associated with immune-mediated hemolytic anemia in dogs: Ten cases
(1982–1987). Journal of the American Veterinary Medical Association 195,
246–250.
Kol, A., Borjesson, D.L., 2010. Application of thromboelastography/
thromboelastometry to veterinary medicine. Veterinary Clinical Pathology 39,
405–416.
Kristensen, A.T.,Wiinberg, B., Jessen, L.R., Andreasen, E., Jensen, A.L., 2008. Evaluation
of human recombinant tissue factor-activated thromboelastography in 49 dogs
with neoplasia. Journal of Veterinary Internal Medicine 22, 140–147.
Li, N., 2008. Platelet–lymphocyte cross-talk. Journal of Leukocyte Biology 83, 1069–
1078.
McManus, P.M., Craig, L.E., 2001. Correlation between leukocytosis and necropsy
findings in dogs with immune-mediated hemolytic anemia: 34 cases (1994–
1999). Journal of the American Veterinary Medical Association 218, 1308–1313.
Mischke, V.R., 1998. Hemostatic disorders as a complication of autoimmune
hemolytic anemia in dogs. Deutsche Tierärztliche Wochenschrift 105, 13–16.
Mitchell, K.D., Kruth, S.A., Wood, R.D., Jefferson, B., 2009. Serum acute phase protein
concentrations in dogs with autoimmune hemolytic anemia. Journal of
Veterinary Internal Medicine 23, 585–591.
Nielsen, V.G., Lyerly III, R.T., Gurley, W.Q., 2004. The effect of dilution on plasma
coagulation kinetics determined by thromboelastographic is dependent on
antithrombin activity and mode of activation. Anesthesia and Analgesia 99,
1587–1592.
Okano, S., Yoshida, M., Fukushima, U., Higuchi, S., Takase, K., Hagio, M., 2002.
Usefulness of systemic inflammatory response syndrome criteria as an index for
prognosis judgement. Veterinary Record 150, 245–246.
Otto, C.M., Rieser, T.M., Brooks, M.B., Russell, M.W., 2000. Evidence of
hypercoagulability in dogs with parvoviral enteritis. Journal of the American
Veterinary Medicine Association 217, 1500–1504.
Palmer, K.G., King, L.G., Van Winkle, T.J., 1998. Clinical manifestations and
associated disease syndromes in dogs with cranial venal cava thrombosis: 17
cases (1989–1996). Journal of the American Veterinary Medical Association
213, 220–224.
Pullarkat, V., Ngo, M., Iqbal, S., Espina, B., Liebman, H.A., 2002. Detection of lupus
anticoagulant identifies patients with autoimmune haemolytic anaemia at
increased risk for venous thromboembolism. British Journal of Haematology
118, 1166–1169.
Rose, L., Bedard, C., Dunn, M., 2008. Effects of prednisone administration on
thromboelastography parameters in healthy beagles. Journal of Veterinary
Internal Medicine 22, 739.
Rother, R.P., Bell, L., Hillmen, P., Gladwin, M.T., 2005. The clinical sequelae of
intravascular hemolysis and extracellular plasma hemoglobin – A novel
mechanism of human disease. Journal of the American Medical Association
293, 1653–1662.
Scott-Moncrieff, J.C., Treadwell, N.G., McCullough, S.M., Brooks, M.B., 2001.
Hemostatic abnormalities in dogs with primary immune-mediated hemolytic
anemia. Journal of the American Animal Hospital Association 37, 220–227.
Sinnott, V.B., Otto, C.M., 2009. Use of thromboelastography in dogs with immune-
mediated hemolytic anemia: 39 cases (2000–2008). Journal of Veterinary
Emergency and Critical Care 19, 484–488.
Sorensen, B., Johansen, P., Christiansen, K., Woelke, M., Ingerslev, J., 2003. Whole
blood coagulation thromboelastographic profiles employing minimal tissue
factor activation. Journal of Thrombosis and Haemostasis 1, 551–558.
Spiezia, L., Radu, C., Marchioro, P., Bertini, D., Rossetto, V., Castelli, M., Pagnan, A.,
Sørensen, B., Simioni, P., 2008. Peculiar whole blood rotation
thromboelastometry (Rotem) profile in 40 sideropenic anaemia patients.
Thrombosis and Haemostasis 100, 1106–1110.
Uitenbroek, D.G., 1997. Sample Size, SISA. http://home.clara.net/sisa/samsize.htm
(accessed 12 January 2007).
Van Winkle, T.J., Bruce, E., 1993. Thrombosis of the portal vein in eleven dogs.
Veterinary Pathology 30, 28–35.
Van Zaane, B., Nur, E., Squizzato, A., Dekkers, O.M., Twickler, M.T., Fliers, E., Gerdes,
V.E., Büller, H.R., Brandjes, D.P., 2009. Hypercoagulable state in Cushing’s
syndrome: A systematic review. Journal of Clinical Endocrinology and
Metabolism 94, 2743–2750.
Weiss, D.J., Brazzell, J.L., 2006. Detection of activated platelets in dogs with primary
immune-mediated hemolytic anemia. Journal of Veterinary Internal Medicine
20, 682–686.
Whelan, M.F., Rozanski, E.A., O’Toole, T.E., Crawford, S., Holm, J., Cotter, S.M., 2006.
Use of the canine hemolytic anemia objective score (CHAOS) to predict survival
in dogs with immune mediated hemolytic anemia. Journal of Veterinary
Internal Medicine 20, 714–715.
Wiinberg, B., Kristensen, A.T., 2010. Thromboelastography in veterinary medicine.
Seminars in Thrombosis and Hemostasis 36, 747–756.
Wiinberg, B., Jensen, A.L., Rojkjaer, R., Johansson, P., Kjelgaard-Hansen, M.,
Kristensen, A.T., 2005. Validation of human recombinant tissue factor
activated thromboelastography on citrated whole blood from clinically
healthy dogs. Veterinary Clinical Pathology 34, 389–393.
Wiinberg, B., Jensen, A.L., Johansson, P.I., Rozanski, E., Tranholm, M., Kristensen, A.T.,
2008. Thromboelastographic evaluation of hemostatic function in dogs with
disseminated intravascular coagulation. Journal of Veterinary Internal Medicine
22, 357–365.
Zuckerman, L., Cohen, E., Vagher, J.P., Woodward, E., Caprini, J.A., 1981. Comparison
of thromboelastograph with common coagulation tests. Thrombosis and
Haemostasis 46, 752–756.
R. Goggs et al. / The Veterinary Journal 191 (2012) 347–353 353
